HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -18.78% | 10.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.78% | 10.34% | |||
| Cost of Revenue | -9.23% | 14.97% | |||
| Gross Profit | -22.34% | 8.71% | |||
| SG&A Expenses | -9.12% | -9.01% | |||
| Depreciation & Amortization | -1.36% | -1.34% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.49% | -0.85% | |||
| Operating Income | -630.33% | 84.15% | |||
| Income Before Tax | -51.77% | 40.08% | |||
| Income Tax Expenses | -127.06% | 244.07% | |||
| Earnings from Continuing Operations | -46.74% | 37.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.74% | 37.59% | |||
| EBIT | -630.33% | 84.15% | |||
| EBITDA | -37.73% | 40.77% | |||
| EPS Basic | 28.50% | -28.02% | |||
| Normalized Basic EPS | 25.99% | -23.44% | |||
| EPS Diluted | 31.67% | -34.45% | |||
| Normalized Diluted EPS | 25.99% | -23.44% | |||
| Average Basic Shares Outstanding | 5.17% | -4.92% | |||
| Average Diluted Shares Outstanding | 5.17% | -4.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||